Evofem Biosciences, Inc. · OTC:EVFM

Evofem Biosciences — Investor Presentation (February 2021)

25 slides from Evofem Biosciences's investor presentation, Feb 5, 2021

  1. Slide 1: Revolutionizing Women's Sexual and Reproductive Health

    1 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Saundra Pelletier, CEO Revolutionizing Women’s Sexual and Reproductive Health NASDAQ: EVFM February 2021

  2. Slide 2: Forward-Looking Statements

    2 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, y

  3. Slide 3: Evofem Biosciences 101

    3 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Evofem Biosciences 101 Commercial-stage biopharmaceutical company First commercial product launched September 2020 o First-and-only FDA-approved hormone-free, on-demand contraceptive vaginal gel Phase 3 inve

  4. Slide 4: Strong and Experienced Leadership Team

    4 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Strong and Experienced Leadership Team Saundra Pelletier Chief Executive Officer Jay File Chief Financial Officer Kelly Culwell, MD Chief Medical Officer Russ Barrans Chief Commercial Officer 7 years at Evof

  5. Slide 5: The Time is Right for Phexxi

    5 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. The Time is Right for Phexxi In the US today, there are 21 million women at risk for pregnancy who are NOT using hormonal contraception1 5 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015- 20

  6. Slide 6: US Contraceptive Market and Peak Revenue Potential

    6 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief. 2018; 327: 1-14. 2. Estimated market acquisition percentage in segment 3. Gross value of

  7. Slide 7: Solid Monthly Rx Growth

    7 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Solid Monthly Rx Growth 375 967 1100 1378 4 46 132 238 0 250 500 750 1000 1250 1500 1750 2000 Sept. 2020* Oct. 2020* Nov. 2020* Dec. 2020 Refills NRx Source: IQVIA and Knipper through 1 Jan 2021 *Reflects IQ

  8. Slide 8: Broadening the Prescriber Base

    8 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. 2 280 476 531 5901 72 181 297 2 229 548 712 887 0 200 400 600 800 1,000 1,200 Aug. Sep. Oct. Nov. Dec Returning New Prescribers Broadening the Prescriber Base Source: IQVIA data through 1 January 2021 *Refle

  9. Slide 9: Reaching HCPs with Best in Class Sales Team

    9 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Reaching HCPs with “Best in Class” Sales Team 70 Women’s Health sales reps and regional managers • Targeting ~3,500 accounts and the top 12K are the highest prescribing HCPs • Leveraging HCP segmentation too

  10. Slide 10: Telehealth Continues to Drive Leads, Prescriptions

    10 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. Telehealth Continues to Drive Leads, Prescriptions Proprietary Telehealth Solution • Over 960 women have booked appointments through the Phexxi Concierge Experience™ to date1 o~97% of these women left with a Phexxi prescription1 oAverage

  11. Slide 11: Successfully Building Awareness of Phexxi

    11 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Successfully Building Awareness of Phexxi • Over 1.6 million visits to Phexxi.com consumer site since launch1 • Among HCPs since launch: oOver 143,000 visits to HCP-Phexxi.com o17M+ media impressions • 650M

  12. Slide 12: Favorable Data from Post-Concierge Surveys

    12 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. Favorable Data from Post-Concierge Surveys Hormone-free Doesn't impact cycle In the moment Ease of use Product Attributes Underlying Decision to Move Forward with Phexxi1 Source: 83Bar 11 November 2020 1. Question 9: “Why did you decide

  13. Slide 13: Market Access: Commercial Lives

    13 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. • Unique classification in the payor-utilized pricing compendiums First Data Bank and Medispan as “Vaginal pH Modulator” allowing for favorable reimbursement • 56% of commercial lives covered oPhexxi on pre

  14. Slide 14: Market Access: Medicaid

    14 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. • Evofem participating in CDC Medicaid National Drug Rebate Program • Access to Phexxi for 69.8M Medicare lives effective January 1, 2021 Market Access: Medicaid Sources: 1) U.S. Centers for Medicare and Me

  15. Slide 15: Driving the Phexxi Uptake Curve: Direct-To-Consumer Marketing

    15 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. Driving the Phexxi Uptake Curve: Direct-To-Consumer (DTC) Marketing 2021 Phexxi consumer marketing initiatives designed to reach women in a purposeful and targeted manner • High impact campaign launching across television, streaming and

  16. Slide 16: Driving the Phexxi Uptake Curve: DTC

    16 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Social Influencers Partnerships Paid Media Content Product Education Earned Media Driving the Phexxi Uptake Curve: DTC Targeting the Phexxi woman on channels organic to HER, including: (partial list)

  17. Slide 17: NCODA Collaboration: Phexxi for Cancer Patients

    17 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. NCODA Collaboration: Phexxi for Cancer Patients • 800,000 new cases of cancer are reported among women1 • Many cancer treatment protocols require female patients of reproductive age to use birth control while undergoing treatment • Non-h

  18. Slide 18: Over $1 Billion US Market Opportunity

    18 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Sources: 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief. 2018; 327: 1-14 2. Phexxi Forecast Model Assumption. There are 21 million wome

  19. Slide 19: Pipeline: EVO100 for Prevention of Chlamydia and Gonorrhea in Women

    19 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. PIPELINE: EVO100 for Prevention of Chlamydia and Gonorrhea in Women EVO100 is investigational and safety and efficacy have not been established.

  20. Slide 20: STI Prevention: A Large Market Opportunity

    20 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. STI Prevention: A Large Market Opportunity • CDC estimates 1 in 5 people have an STI = 68M infections3 • 78M sexually active women in US are potentially at risk for STIs4 • Chlamydia and Gonorrhea infection

  21. Slide 21: EVOGUARD Phase 3 Trial Underway

    21 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. EVOGUARD Phase 3 Trial Underway • Phase 3, double-blind, placebo-controlled study to evaluate the efficacy of EVO100 in the prevention of urogenital Chlamydia trachomatis (CT) and Neisseria gonorrhea (GC) i

  22. Slide 22: EVO100: Timeline to Approval

    22 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. EVO100: Timeline to Approval 2021 2022 2023 Potential US Approval & Commercial Launch NDA Submission2 Top-Line Results1 Initiated Pivotal Phase 3 Trial • FDA Fast Track designation for prevention of chlamyd

  23. Slide 23: Financial Overview

    23 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Financial Overview • Shares outstanding: 81.3M1 • Warrants outstanding: 10.4M2 oWeighted average exercise price $4.54 • Unrestricted cash $86.7M at September 30, 2020 • Raised $25M in Oct. 2020 from Adjuvan

  24. Slide 24: Our Time is Now

    24 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. For investor discussions only. Our Time is Now • Phexxi is the first and only hormone-free prescription contraception women control and use only when needed oUS sales opportunity over $1 billion oLaunching DTC campaign Q1 2021 to catalyz

  25. Slide 25: 2021 Evofe Biosciences, Inc. ®

    25 ©2019 Evofem Biosciences, Inc. 2021 Evofe Biosciences, Inc. ®

Evofem Biosciences — Investor Presentation (February 2021) on 6ix